I-Mab Adr (IMAB) has disclosed a new risk, in the Trade Secrets category.
The evolving landscape of U.S. patent law presents a significant risk to I-Mab Adr’s ability to safeguard its drug candidates. The shift to a first-to-file system, coupled with the potential for delayed public disclosure of discoveries, increases the uncertainty around securing patent protection. Recent Supreme Court decisions, like Amgen Inc. v. Sanofi, have further narrowed the scope of patentable subject matter and emphasized the need for comprehensive enablement in patent specifications. This legal volatility, along with unpredictable changes in European patent laws, could materially weaken I-Mab Adr’s patent portfolio and its capacity to defend its intellectual property.
Overall, Wall Street has a Strong Buy consensus rating on IMAB stock based on 4 Buys.
To learn more about I-Mab Adr’s risk factors, click here.
